0001213900-19-017826.txt : 20190912 0001213900-19-017826.hdr.sgml : 20190912 20190912080957 ACCESSION NUMBER: 0001213900-19-017826 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20190912 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20190912 DATE AS OF CHANGE: 20190912 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMAG PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000792977 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042742593 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-10865 FILM NUMBER: 191089542 BUSINESS ADDRESS: STREET 1: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 6174983300 MAIL ADDRESS: STREET 1: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: AMAG PHARMACEUTICALS INC. DATE OF NAME CHANGE: 20070724 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED MAGNETICS INC DATE OF NAME CHANGE: 19920703 8-K 1 f8k091219_amagpharma.htm CURRENT REPORT
0000792977 false NASDAQ 0000792977 2019-09-11 2019-09-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): September 12, 2019

 

 

 

AMAG PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of incorporation)

     
001-10865   04-2742593
(Commission File Number)   (IRS Employer Identification No.)
     
1100 Winter Street    
Waltham, Massachusetts   02451
(Address of principal executive offices)   (Zip Code)

(617) 498-3300

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☒ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.01 per share   AMAG   NASDAQ Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

 

Item 8.01. Other Events.

 

On September 12, 2019, AMAG Pharmaceuticals, Inc. (the “Company”) issued a press release presenting a letter to its shareholders regarding Caligan Partners LP’s solicitation of written consents from the Company’s shareholders. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit

Number

   Description
99.1   Press release issued by AMAG Pharmaceuticals, Inc. on September 12, 2019.

 

 1 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AMAG PHARMACEUTICALS, INC.
   
  By: /s/ Joseph D. Vittiglio
   

Joseph D. Vittiglio

Executive Vice President, General Counsel,
Quality & Corporate Secretary

   
  Date: September 12, 2019

 

 

 2 

 

 EX-99.1 2 f8k091219ex99-1_amag.htm PRESS RELEASE ISSUED BY AMAG PHARMACEUTICALS, INC. ON SEPTEMBER 12, 2019

Exhibit 99.1

 

 

AMAG Sends Letter to Shareholders

 

Urges Shareholders Take No Action On Caligan Consent Solicitation

 

WALTHAM, Mass., Sept. 12, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) (“AMAG” or the “Company”) today issued the following letter, which will be mailed to its shareholders.

 

AMAG’s Board urges all AMAG shareholders to refrain from taking any action (including returning any consent card sent by Caligan) at this time. The Company’s Board of Directors, in consultation with its advisors, is reviewing Caligan’s solicitation materials and will advise AMAG’s shareholders of its recommendation regarding Caligan’s solicitation in due course.

 

*** SHAREHOLDERS SHOULD TAKE NO ACTION ON CALIGAN’S CONSENT SOLICITATION ***

 

September 12, 2019

 

Dear AMAG Shareholder:

 

You may soon receive consent solicitation materials from Caligan Partners LP, a hedge fund that accumulated its entire stake in AMAG Pharmaceuticals, Inc. within the past three months. Caligan has indicated that it intends to seek your written consent to remove and replace four members of your AMAG Board of Directors. Additionally, the Company is carefully reviewing the proposed ideas from Caligan, as it is concerned that certain actions pushed by Caligan may be destructive to the long-term value of the Company.

 

The Board is committed to acting in the best interest of shareholders and maximizing long-term value creation, and remains steadfast in its belief that any corporate action taken must be for the benefit of all AMAG shareholders. Since 2017, the Company has made significant progress executing on its ambitious five-year strategic plan to develop and commercialize innovative products. In this timeframe, AMAG has successfully transformed from a specialty pharmaceuticals company with only two assets into a pharmaceutical company with four commercial therapies and two development-stage programs all while strengthening the financial profile of the Company. AMAG has streamlined and diversified its product portfolio and development pipeline through the divestiture of the CBR business and the acquisitions of AMAG-423 and ciraparantag and significantly strengthened its balance sheet through debt reduction and salesforce consolidation. Your Board believes that the removal of four highly-qualified and experienced members of the Board would be detrimental to the Company and our shareholders.

 

*** WE STRONGLY URGE YOU TO WAIT FOR AMAG’s CONSENT REVOCATION STATEMENT AND

GREEN CONSENT REVOCATION CARD FORM ***

 

It is imperative that shareholders take the necessary time to review relevant information, including the recommendation of AMAG’s Board, before taking any action with respect to Caligan’s consent solicitation. The Company intends to mail to you a consent revocation statement and accompanying GREEN consent revocation card, which will explain in more detail the Board’s reasons for opposing Caligan’s consent solicitation.

 

***DO NOT SIGN ANY WHITE CALIGAN CONSENT***

 

We urge all shareholders to refrain from taking any action at this time and to WAIT for AMAG’s consent revocation statement and GREEN consent revocation card. In the meantime, we urge all shareholders to disregard Caligan’s consent efforts and discard any materials that may have been sent to you by Caligan. If you have any questions or require assistance, please contact AMAG’s proxy solicitor, Innisfree M&A Incorporated, by calling toll-free at (877) 750-0926 or collect at (212) 750-5833.

 

Sincerely,

 

Gino Santini William K. Heiden
Chairman of the Board President and Chief Executive Officer

 

 

 

 

Important Additional Information and Where to Find It

In connection with the consent solicitation initiated by Caligan, the Company has filed a preliminary consent revocation statement and accompanying GREEN consent revocation card and other relevant documents with the Securities and Exchange Commission (the “SEC”). SHAREHOLDERS ARE STRONGLY ENCOURAGED TO READ THE COMPANY’S DEFINITIVE CONSENT REVOCATION STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO), ACCOMPANYING GREEN CONSENT REVOCATION CARD AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders may obtain a free copy of the definitive consent revocation statement, any amendments or supplements to the consent revocation statement and other documents that the Company files with the SEC at the SEC’s website at www.sec.gov or the Company’s website at http://ir.amagpharma.com as soon as reasonably practicable after such materials are electronically filed with, or furnished to, the SEC.

 

Certain Information Regarding Participants to the Solicitation

The Company, its directors and certain of its officers and employees will be deemed participants in the solicitation of consent revocations from the Company’s shareholders. Information regarding the direct and indirect interests, by security holdings or otherwise of the Company’s directors and executive officers is set forth in the Company’s definitive proxy statement for the 2019 Annual Meeting of Stockholders filed with the SEC on April 15, 2019. To the extent that such participants’ holdings in the Company’s securities have changed since the filing of such proxy statement, such changes have been reflected on Statements of Change in Ownership on Form 4 filed with the SEC. These documents can be found on the SEC’s website at www.sec.gov or the Company’s website at http://ir.amagpharma.com. Updated information regarding the identities of potential participants, and their direct or indirect interests, by security holdings or otherwise, will be set forth in the Company’s consent revocation statement in connection with the solicitation of consent revocations from the Company’s shareholders and other relevant documents to be filed with the SEC.

 

Forward-Looking Statements

This communication contains forward-looking information about AMAG within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, the belief that any corporate action taken must be for the benefit of all Company shareholders and must be rooted in a strong understanding of the pharmaceutical industry, AMAG’s business and its important milestones ahead, beliefs about AMAG’s strategy and long-term value creation, beliefs about AMAG’s strategic plan and implementation thereof, beliefs about AMAG’s financial profile and its Board and expectations as to and beliefs about the consent solicitation are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.

 

Such risks and uncertainties include, among others, the impact and results of the consent solicitation and other activism activities by Caligan and/or other activist investors; as well as those risks identified in AMAG’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2018, its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2019 and June 30, 2019 and subsequent filings with the SEC which are available at the SEC’s website at www.sec.gov. Any such risks and uncertainties could materially and adversely affect AMAG’s results of operations, its profitability and its cash flows, which would, in turn, have a significant and adverse impact on AMAG’s stock price. AMAG cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. AMAG disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

 

About AMAG

AMAG is a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs. The company does this by leveraging its development and commercial expertise to invest in and grow its pharmaceutical products across a range of therapeutic areas, including women’s health. For additional company information, please visit www.amagpharma.com.

 

AMAG Pharmaceuticals Contacts:

Investors: Media:
Linda Lennox Rushmie Nofsinger
908-627-3424 781-530-6838

 

 

 

 

 

 EX-101.SCH 3 amag-20190912.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 amag-20190912_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 amag-20190912_pre.xml XBRL PRESENTATION FILE GRAPHIC 6 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end GRAPHIC 7 image_001.jpg GRAPHIC begin 644 image_001.jpg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end XML 9 f8k091219_amagpharma_htm.xml IDEA: XBRL DOCUMENT 0000792977 2019-09-11 2019-09-12 iso4217:USD shares iso4217:USD shares 0000792977 false NASDAQ 8-K 2019-09-12 AMAG PHARMACEUTICALS, INC. DE 001-10865 04-2742593 1100 Winter Street Waltham MA 02451 (617) 498-3300 false true false false Common Stock, par value $0.01 per share AMAG false false XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k091219_amagpharma.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "f8k091219_amagpharma.htm" ] }, "labelLink": { "local": [ "amag-20190912_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "amag-20190912_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "amag-20190912.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "amag", "nsuri": "http://amagpharma.com/20190912", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "f8k091219_amagpharma.htm", "contextRef": "From2019-09-11to2019-09-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://amagpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "f8k091219_amagpharma.htm", "contextRef": "From2019-09-11to2019-09-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://amagpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } ZIP 14 0001213900-19-017826-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-19-017826-xbrl.zip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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 1 97 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://amagpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k091219_amagpharma.htm amag-20190912.xsd amag-20190912_lab.xml amag-20190912_pre.xml f8k091219ex99-1_amag.htm image_001.jpg http://xbrl.sec.gov/dei/2019-01-31 true false XML 17 R1.htm IDEA: XBRL DOCUMENT v3.19.2
Cover
Sep. 12, 2019
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 12, 2019
Entity File Number 001-10865
Entity Registrant Name AMAG PHARMACEUTICALS, INC.
Entity Central Index Key 0000792977
Entity Tax Identification Number 04-2742593
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1100 Winter Street
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02451
City Area Code (617)
Local Phone Number 498-3300
Written Communications false
Soliciting Material true
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol AMAG
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Elected Not To Use the Extended Transition Period false